• Optimal antibody combinations and Fc binding inhibit SARS-CoV-2 in vivo

    12 days ago - By News Medical

    A recent study by researchers at the University of North Carolina at Chapel Hill and The Rockefeller University and published on the preprint server bioRxiv in September 2020 shows that a combination of neutralizing antibodies with intact Fc effector function can effectively reduce the viral load and prevent infection.
    Read more ...

     

  • Azelastine antihistamine inhibits SARS-CoV-2 infection in nasal tissue in vitro

    13 days ago - By News Medical

    In a study published on the bioRxiv preprint server, researchers from the University of Pécs, University of Vienna, and CEBINA GmbH, Vienna, show the ability of the antihistamine azelastine to inhibit SARS-CoV-2 infection in human nasal tissue in vitro.
    Read more ...